Back to Search Start Over

Predicted basal metabolic rate and cancer risk in the European Prospective Investigation into Cancer and Nutrition

Authors :
Elisabete Weiderpass
Kim Overvad
Giovanna Masala
Guy Fagherazzi
Rudolf Kaaks
Daniel Redondo-Sánchez
Sabina Rinaldi
Ulrica Ericson
Dagfinn Aune
Pilar Amiano
Therese Haugdahl Nøst
Antonia Trichopoulou
Rosario Tumino
Paula Jakszyn
Neil Murphy
Elio Riboli
Tilman Kühn
Francesca Mancini
Heinz Freisling
Bas Bueno-de-Mesquita
Marie-Christine Boutron-Ruault
Maria Santucci de Magistris
Inge Huybrechts
Marc J. Gunter
Carlotta Sacerdote
Nathalie Kliemann
Christina C. Dahm
Vivian Viallon
Vittorio Krogh
Lena Maria Nilsson
Isabel Drake
Anne M. May
Heiner Boeing
Matthias B. Schulze
Carlo La Vecchia
Anne Tjønneland
Anna Karakatsani
Aurelio Barricarte Gurrea
Konstantinos K. Tsilidis
María Dolores Chirlaque
José Ramón Quirós
Centre international de Recherche sur le Cancer (CIRC)
Université de Paris-Saclay [Villejuif]
Centre de recherche en épidémiologie et santé des populations (CESP)
Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay
Deutsche Krebshilfe Cancer Research UK, CRUK: C8221/A19170, 14136, C570/A16491 Ligue Contre le Cancer Bundesministerium für Bildung und Forschung, BMBF Bundesministerium für Bildung und Forschung, BMBF Institut National de la Santé et de la Recherche Médicale, Inserm Kræftens Bekæmpelse, DCS Research Councils UK, RCUK Health and Medical Research Fund, HMRF: FIS Zorginstituut Nederland, ZIN PI13/01162, PI13/00061 World Cancer Research Fund, WCRF: ERC‐2009‐AdG 232997 Associazione Italiana per la Ricerca sul Cancro, AIRC National Research Council, NRC Ecumenical Project for International Cooperation, EPIC Institut National de la Santé et de la Recherche Médicale, Inserm European Commission, EU Centre International de Recherche sur le Cancer, CIRC Norway Deutsches Krebsforschungszentrum, DKFZ: DKFZ World Cancer Research Fund, WCRF Cancerfonden NordForsk Medical Research Council, MRC: MR/M012190/1, 1000143
The authors would like to thank the EPIC study participants and staff for their valuable contribution to this research. The authors would also like to thank Mr Bertrand Hemon for his support in preparing the databases and Dr Joseph Rothwell for his support in creating the figures. The coordination of EPIC is financially supported by the European Commission (DGSANCO) and the International Agency for Research on Cancer. The national cohorts are supported by Danish Cancer Society (Denmark)
Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l'Education Nationale, Institut National de la Santé et de la Recherche Médicale (INSERM
France)
German Cancer Aid, German Cancer Research Center (DKFZ), Federal Ministry of Education and Research (BMBF
Germany)
the Hellenic Health Foundation (Greece)
Associazione Italiana per la Ricerca sul Cancro‐AIRC‐Italy and National Research Council (Italy)
Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF)
ERC‐2009‐AdG 232997 and Nordforsk, Nordic Centre of Excellence Programme on Food, Nutrition and Health (Norway)
Health Research Fund (FIS) of the Spanish Ministry of Health (FIS
PI13/00061 to Granada
PI13/01162 to EPIC‐Murcia), Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra and the Catalan Institute of Oncology (Spain)
Swedish Cancer Society, Swedish Research Council and County Councils of Skåne and Västerbotten (Sweden)
Cancer Research UK (14136 to EPIC‐Norfolk
C570/A16491 and C8221/A19170 to EPIC‐Oxford), Medical Research Council (1000143 to EPIC‐Norfolk, MR/M012190/1 to EPIC‐Oxford
United Kingdom).
Source :
Dipòsit Digital de la UB, Universidad de Barcelona, Kliemann, N, Murphy, N, Viallon, V, Freisling, H, Tsilidis, K K, Rinaldi, S, Mancini, F R, Fagherazzi, G, Boutron-Ruault, M-C, Boeing, H, Schulze, M B, Masala, G, Krogh, V, Sacerdote, C, Santucci de Magistris, M, Bueno-de-Mesquita, B, Weiderpass, E, Kühn, T, Kaaks, R, Jakszyn, P, Redondo-Sánchez, D, Amiano, P, Chirlaque, M-D, Barricarte Gurrea, A, Ericson, U, Drake, I, Nøst, T H, Aune, D, May, A M, Tjønneland, A, Dahm, C C, Overvad, K, Tumino, R, Ramón Quirós, J, Trichopoulou, A, Karakatsani, A, La Vecchia, C, Nilsson, L M, Riboli, E, Huybrechts, I & Gunter, M J 2020, ' Predicted basal metabolic rate and cancer risk in the European Prospective Investigation into Cancer and Nutrition ', International Journal of Cancer, vol. 147, no. 3, pp. 648-661 . https://doi.org/10.1002/ijc.32753, International Journal of Cancer, International Journal of Cancer, Wiley, 2020, 147 (3), pp.648-661. ⟨10.1002/ijc.32753⟩
Publication Year :
2020
Publisher :
Wiley, 2020.

Abstract

Emerging evidence suggests that a metabolic profile associated with obesity may be a more relevant risk factor for some cancers than adiposity per se. Basal metabolic rate (BMR) is an indicator of overall body metabolism and may be a proxy for the impact of a specific metabolic profile on cancer risk. Therefore, we investigated the association of predicted BMR with incidence of 13 obesity-related cancers in the European Prospective Investigation into Cancer and Nutrition (EPIC). BMR at baseline was calculated using the WHO/FAO/UNU equations and the relationships between BMR and cancer risk were investigated using multivariable Cox proportional hazards regression models. A total of 141,295 men and 317,613 women, with a mean follow-up of 14 years were included in the analysis. Overall, higher BMR was associated with a greater risk for most cancers that have been linked with obesity. However, among normal weight participants, higher BMR was associated with elevated risks of esophageal adenocarcinoma (hazard ratio per 1-standard deviation change in BMR [HR 1-SD]: 2.46; 95% CI 1.20; 5.03) and distal colon cancer (HR 1-SD: 1.33; 95% CI 1.001; 1.77) among men and with proximal colon (HR 1-SD: 1.16; 95% CI 1.01; 1.35), pancreatic (HR 1-SD: 1.37; 95% CI 1.13; 1.66), thyroid (HR 1-SD: 1.65; 95% CI 1.33; 2.05), postmenopausal breast (HR 1-SD: 1.17; 95% CI 1.11; 1.22) and endometrial (HR 1-SD: 1.20; 95% CI 1.03; 1.40) cancers in women. These results indicate that higher BMR may be an indicator of a metabolic phenotype associated with risk of certain cancer types, and may be a useful predictor of cancer risk independent of body fatness.

Details

ISSN :
00207136 and 10970215
Database :
OpenAIRE
Journal :
Dipòsit Digital de la UB, Universidad de Barcelona, Kliemann, N, Murphy, N, Viallon, V, Freisling, H, Tsilidis, K K, Rinaldi, S, Mancini, F R, Fagherazzi, G, Boutron-Ruault, M-C, Boeing, H, Schulze, M B, Masala, G, Krogh, V, Sacerdote, C, Santucci de Magistris, M, Bueno-de-Mesquita, B, Weiderpass, E, Kühn, T, Kaaks, R, Jakszyn, P, Redondo-Sánchez, D, Amiano, P, Chirlaque, M-D, Barricarte Gurrea, A, Ericson, U, Drake, I, Nøst, T H, Aune, D, May, A M, Tjønneland, A, Dahm, C C, Overvad, K, Tumino, R, Ramón Quirós, J, Trichopoulou, A, Karakatsani, A, La Vecchia, C, Nilsson, L M, Riboli, E, Huybrechts, I & Gunter, M J 2020, ' Predicted basal metabolic rate and cancer risk in the European Prospective Investigation into Cancer and Nutrition ', International Journal of Cancer, vol. 147, no. 3, pp. 648-661 . https://doi.org/10.1002/ijc.32753, International Journal of Cancer, International Journal of Cancer, Wiley, 2020, 147 (3), pp.648-661. ⟨10.1002/ijc.32753⟩
Accession number :
edsair.doi.dedup.....d7b3c044bc8c6175e352f66b80c0cf99